重症监护病房内的多重耐药菌肠道定植:系统评价与荟萃分析
该系统评价与荟萃分析检索了PubMed、Embase和Web of Science(2010至2023年),纳入14项观察性研究、37,305例ICU患者,均在入ICU 48小时内及后续一个或多个时间点采集肛周或直肠拭子。多重耐药菌(MDRO)定义为耐多药非铜绿假单胞菌革兰阴性菌(NP-GN)、假单胞菌属和耐万古霉素肠球菌(VRE)。主要结局为ICU期间MDRO肠道获得定植的发生率,合并发生率为5%(范围1-43%),合并发生率为12.2/1000患者日(95%CI 8.1-18.6),获得定植的中位时间为入ICU后4至26天。6项研究拟合曲线显示,肠道MDRO定植每天准线性增加1.41%,并在ICU住院30天内保持稳定(R2=0.50,p<0.01)。
要点
- 14项研究、37,305例ICU患者中,肠道MDRO获得定植的合并发生率为5%(范围1-43%),合并发生率为12.2/1000患者日(95%CI 8.1-18.6)。
- 获得定植的中位时间为入ICU后4至26天。
- NP-GN与假单胞菌属的结果相似,VRE因数据不足无法评估。
- 6项研究拟合曲线显示肠道MDRO定植每天准线性增加1.41%,并在ICU住院30天内保持稳定(R2=0.50,p<0.01)。
适用人群与场景
- ICU患者,纳入在入ICU 48小时内及后续一个或多个时间点采集肛周或直肠拭子的观察性研究。
- MDRO定义为耐多药非铜绿假单胞菌革兰阴性菌(NP-GN)、假单胞菌属和耐万古霉素肠球菌(VRE)。
诊断标准与关键阈值
- MDRO定义:耐多药非铜绿假单胞菌革兰阴性菌(NP-GN)、假单胞菌属、耐万古霉素肠球菌(VRE)。
- 肠道MDRO获得定植定义为入ICU后新检出任何MDRO(即基线不存在)。
研究设计与关键结果
- 系统评价与荟萃分析,检索PubMed、Embase和Web of Science(2010至2023年),初筛482项研究,最终纳入14项观察性研究、37,305例患者。
- 主要结局:ICU住院期间肠道MDRO获得定植的合并发生率为5%(范围1-43%),合并发生率为12.2/1000患者日(95%CI 8.1-18.6)。
- 获得定植的中位时间为入ICU后4至26天。
- NP-GN与假单胞菌属的结果相似,VRE因数据不足无法评估。
- 6项研究拟合曲线显示,肠道MDRO定植每天准线性增加1.41%,并在ICU住院30天内保持稳定(R2=0.50,p<0.01)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入14项观察性研究。
- 研究已注册于PROSPERO,CRD42023481569。
对床旁实践的改变
- 作者认为,这些数据可能指导未来旨在预防ICU肠道MDRO获得定植的干预措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Gut colonization with multidrug-resistant organisms (MDRO) frequently precedes infection among patients in the intensive care unit (ICU), although the dynamics of colonization are not completely understood. We performed a systematic review and meta-analysis of ICU studies which described the cumulative incidence and rates of MDRO gut acquisition.
METHODS: We systematically searched PubMed, Embase, and Web of Science for studies published from 2010 to 2023 reporting on gut acquisition of MDRO in the ICU. MDRO were defined as multidrug resistant non-Pseudomonas Gram-negative bacteria (NP-GN), Pseudomonas spp., and vancomycin-resistant Enterococcus (VRE). We included observational studies which obtained perianal or rectal swabs at ICU admission (within 48 h) and at one or more subsequent timepoints. Our primary outcome was the incidence rate of gut acquisition of MDRO, defined as any MDRO newly detected after ICU admission (i.e., not present at baseline) for all patient-time at risk. The study was registered with PROSPERO, CRD42023481569.
RESULTS: Of 482 studies initially identified, 14 studies with 37,305 patients met criteria for inclusion. The pooled incidence of gut acquisition of MDRO during ICU hospitalization was 5% (range: 1-43%) with a pooled incidence rate of 12.2 (95% CI 8.1-18.6) per 1000 patient-days. Median time to acquisition ranged from 4 to 26 days after ICU admission. Results were similar for NP-GN and Pseudomonas spp., with insufficient data to assess VRE. Among six studies which provided sufficient data to perform curve fitting, there was a quasi-linear increase in gut MDRO colonization of 1.41% per day which was stable through 30 days of ICU hospitalization (R2 = 0.50, p < 0.01).
CONCLUSIONS: Acquisition of gut MDRO was common in the ICU and increases with days spent in ICU through 30 days of follow-up. These data may guide future interventions seeking to prevent gut acquisition of MDRO in the ICU.
参考来源
- Heath MR, Fan W, Leu CS, et al. Gut colonization with multidrug resistant organisms in the intensive care unit: a systematic review and meta-analysis. Crit Care. 2024. PMID: 38943133. doi:10.1186/s13054-024-04999-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。